Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CHOLESTYRAMINE RESIN

All products: general benefit

Other products in the same Health Canada class (C10A, C10AC) — coverage varies; not interchangeable

  • Colesevelam (Lodalis): general benefit, Listing status unconfirmed
  • Atorvastatin (Lipitor): general benefit
  • Bezafibrate (Bezalip): general benefit
  • Fenofibrate (Lipidil): general benefit, Not a benefit
  • Fluvastatin (Lescol): general benefit, Not a benefit
  • Gemfibrozil (Lopid): general benefit, Not a benefit

9 more in the class list below

Jamp-Cholestyramine 4g/Sachet · DIN 02478595 · · Oral Pd-Pouch Pk

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Cholestyramine 4g/Sachet · DIN 02478595 Manufacturer: Jamp Pharma Corporation; listing date 2019-09-30 Health Canada: Marketed since 2020-02-10 · brand JAMP-CHOLESTYRAMINE · ATC C10AC01 COLESTYRAMINE · form Powder for suspension · route Oral · ingredients CHOLESTYRAMINE RESIN 4 G/SACHET · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Cholestyramine 4g/Sachet: Formulary list price $0.9217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96937 · Verify on the e-Formulary ↗ (DIN 02478595)

Source record
DIN 02478595: Jamp-Cholestyramine 4g/Sachet Raw flags: chronicUseMed=Y, sec3=Y Item: 240600003; group id 298; item number 0651; lccId None; manufacturer id JPC Source form: Oral Pd-Pouch Pk; strength: None Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.9217; ministry $0.9217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02478595 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96937
Interchangeable products
Cholestyramine-Odan 4g/sachet · DIN 02455609 · $0.9217 Olestyr 4g/9g Pk · DIN 02210320 · $0.9217 Questran Light 4g Pk · DIN 01918486 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab

EVOLOCUMAB

· 1 products · Limited Use, codes 527, 737 · strengths: 140mg/mL · Inj Sol-Pref Syr Autoinj Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS OLESTYR (cholestyramine resin) is indicated in adults:  As adjunctive therapy to diet and exercise for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low -density lipoproteins). Such reduction of serum cholesterol may reduce the risks of atherosclerotic coronary artery disease and myocardial infarction.  For lowering elevated cholesterol in patients with combined hypercholesterolemia and hypertriglyceridemia. OLESTYR is not indicated where hypertriglyceridemia is the abnormality of most concern.  As a symptomatic control of bile acid induced diarrhea due to short bowel syndrome.  For the relief of pruritus associated with partial biliary obstruction. 1.1 Pediatrics Pediatrics (birth to 18 year of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of OLESTYR in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use (see 4.2 Special Populations and Conditions; 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (over 65 years of … https://pdf.hres.ca/dpd_pm/00064696.PDF PM date: Mar 15, 2012 Source product: OLESTYR; DIN 02210320; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.